FIELD: medicine.
SUBSTANCE: method for prediction the recurrence-free survival period in cervical cancer (CC) is implemented by blood plasma catalase activity test, and the local process of cervical cancer (FIGO stage Ib-IIa) with activity 0.041 to 0.113 mmol/min/l in the patients enables predicting 50% probability of the 18-month period of the recurrence-free survival period, while blood plasma catalase activity 0.008 to 0.035 mmol/min/l shows 80% probability of the recurrence-free survival period.
EFFECT: prediction of the recurrence-free survival period in local cervical cancer.
6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RECURRENCE-FREE SURVIVAL IN CERVICAL CANCER | 2012 |
|
RU2487359C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY CANCER TISSUE GLUTATHIONE REDUCTASE ACTIVITY TEST | 2012 |
|
RU2483304C1 |
| METHOD FOR REDUCING STIFFNESS OF RED BLOOD CELL MEMBRANE IN PATIENTS SUFFERING FROM CERVICAL CANCER | 2013 |
|
RU2523345C1 |
| METHOD FOR PREDICTING THE CLINICAL OUTCOME OF LOCALLY ADVANCED FORMS OF CERVICAL CANCER | 2018 |
|
RU2674675C2 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR UTERINE CANCER | 2012 |
|
RU2488823C1 |
| CERVICAL CANCER STAGING METHOD | 2016 |
|
RU2645111C2 |
| METHOD FOR PREDICTING THE PROGRESSION OF CERVICAL CANCER IN PATIENTS WITH STAGE IIB | 2022 |
|
RU2789500C1 |
| METHOD FOR DIAGNOSIS OF METASTASES TO LYMPH NODES OF SMALL PELVIS IN PATIENTS WITH RESECTABLE CERVICAL CANCER | 2020 |
|
RU2750769C2 |
| METHOD FOR PREDICTION OF CERVICAL CANCER METASTASES | 2010 |
|
RU2436102C1 |
| METHOD FOR PREVENTION OF HAEMATOGENOUS METASTASIS IN SURGICAL TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER | 2015 |
|
RU2591612C1 |
